IDNA
iShares Genomics Immunology and Healthcare ETF
Price Chart
Latest Quote
$31.71
+0.54 (+1.73%)
Current Price
| Previous Close | $31.17 |
| Open | $31.44 |
| Day High | $32.00 |
| Day Low | $31.44 |
| Volume | 34,703 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.03% |
| Net Assets | $163.14M |
| Expense Ratio | 0.47% |
| Category | Health |
| Fund Family | iShares |
| Net Asset Value | $31.16 |
| Premium/Discount | 1.78% |
| Quarterly Dividend Yield | 1.03% |
| P/E Ratio | 20.38 |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $29.74 |
| SMA50 | $29.72 |
| SMA200 | $27.50 |
| RSI | 74.47 |
| ATR | 0.7321 |
| Rel Volume | 1.19 |
Performance History
| Week | +6.16% |
| Month | +8.13% |
| Quarter | +13.28% |
| 6 Months | +20.35% |
| YTD | +21.45% |
| Year | +57.09% |
| 3 Years | +35.75% |
| 5 Years | -30.35% |
| 10 Years | +36.81% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $31.71 | 34,700 |
| 2026-06-23 | $31.17 | 20,400 |
| 2026-06-22 | $30.70 | 52,000 |
| 2026-06-18 | $30.56 | 14,900 |
| 2026-06-17 | $30.39 | 21,800 |
| 2026-06-16 | $29.87 | 27,100 |
| 2026-06-15 | $29.96 | 16,400 |
| 2026-06-12 | $29.65 | 17,300 |
| 2026-06-11 | $29.40 | 23,100 |
| 2026-06-10 | $28.53 | 15,900 |
| 2026-06-09 | $29.08 | 5,400 |
| 2026-06-08 | $28.94 | 9,800 |
| 2026-06-05 | $29.02 | 39,700 |
| 2026-06-04 | $29.83 | 62,100 |
| 2026-06-03 | $28.77 | 18,300 |
| 2026-06-02 | $28.56 | 69,500 |
| 2026-06-01 | $29.20 | 31,100 |
| 2026-05-29 | $29.75 | 22,600 |
| 2026-05-28 | $29.95 | 62,400 |
| 2026-05-27 | $29.69 | 17,900 |
| 2026-05-26 | $29.63 | 33,700 |
About iShares Genomics Immunology and Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.
đ° Latest News
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Zacks âĸ 2026-06-23T16:00:00Z
3 ETFs For the Coming Genomics Revolution
MarketBeat âĸ 2026-06-07T12:45:00Z
AI Scare Back in the Market: ETFs That Stayed Steady
Zacks âĸ 2026-02-24T13:00:00Z
Here's Why Biotech ETFs Are Rallying Hard
Zacks âĸ 2026-01-09T15:00:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.